KIF16B

Across TCGA pan-cancer cohorts, KIF16B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated KIF16B data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher KIF16B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated KIF16B expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where KIF16B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.295	0.818	.001	24	view →
LUAD	OS	Quartile	III,IV	0.839	0.250	.010	10	view →
HNSC	DFS	Median	II,III,IV	0.988	0.907	.010	6	view →
GBM	DFS	Median	All	0.295	0.439	.035	4	view →
PDAC	OS	Median	IV	0.836	0.491	.024	3	view →
LSCC	DFS	Tertile	III,IV	0.874	0.373	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

KIF16B–CCRCC (DFS)

Open the CCRCC breakdown →